| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.08 | 0.2 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |